In this article, what is known about mechanisms involved in partial protection against malaria induced by RTS,S is reviewed.
Accessibility of habitats in urban settings presents a major challenge because the majority of compounds are fenced for security reasons.
The World Health Organization provides treatment guidelines for children from six months onwards, without specific treatment guidelines for the younger infants. A number of recent reports however suggest that the burden in this young age group may be underestimated.
Both fungus isolates are effective and persistent at low concentrations and short exposure times.
CHWs can safely and effectively use RDTs in their management of febrile children; however, cost-effectiveness of RDTs is limited in zones of high malaria prevalence.
Artemether/Lumefantrine (Coartem(R)) has been used as a first-line treatment for uncomplicated Plasmodium falciparum infection since 2004 in Ethiopia. In the present study the therapeutic efficacy of artemether/lumefantrine for the treatment of uncomplicated P. falciparum infection in Kersa, Jima zone, South-west Ethiopia, has been assessed.
The current study proved the excellent therapeutic efficacy of artemether/lumefantrine in the study area and the value of using it.
The completion of Plasmodium genome sequencing and availability of PlasmoDB database has provided a platform for systematic study of parasite genome.
Resistance is futile: A new series of hybrid bis-cations has been synthesized as potent antimalarial agents.
Here we report the identification and molecular characterization of the Anopheles stephensi odorant-binding protein 1 gene (AsteObp1), an Obp1 gene in An. stephensi, a major malaria vector in Asia.